دورية أكاديمية
Natural History of Non-Small-Cell Lung Cancer with Bone Metastases.
العنوان: | Natural History of Non-Small-Cell Lung Cancer with Bone Metastases. |
---|---|
المؤلفون: | Santini D, Barni S, Intagliata S, Falcone A, Ferraù F, Galetta D, Moscetti L, La Verde N, Ibrahim T, Petrelli F, Vasile E, Ginocchi L, Ottaviani D, Longo F, Ortega C, Russo A, Badalamenti G, Collovà E, Lanzetta G, Mansueto G, Adamo V, De Marinis F, Satolli MA, Cantile F, Mancuso A, Tanca FM; Department of Medical Oncology, University of Cagliari, Cagliari, Italy., Addeo R, Russano M, Sterpi M, Pantano F, Vincenzi B, Tonini G; Department of Medical Oncology, University Campus Bio-Medico, Rome, Italy. |
المصدر: | Scientific reports [Sci Rep] 2015 Dec 22; Vol. 5, pp. 18670. Date of Electronic Publication: 2015 Dec 22. |
نوع المنشور: | Journal Article; Multicenter Study |
اللغة: | English |
بيانات الدورية: | Publisher: Nature Publishing Group Country of Publication: England NLM ID: 101563288 Publication Model: Electronic Cited Medium: Internet ISSN: 2045-2322 (Electronic) Linking ISSN: 20452322 NLM ISO Abbreviation: Sci Rep Subsets: MEDLINE |
أسماء مطبوعة: | Original Publication: London : Nature Publishing Group, copyright 2011- |
مواضيع طبية MeSH: | Disease Progression*, Bone Neoplasms/*secondary , Carcinoma, Non-Small-Cell Lung/*pathology , Lung Neoplasms/*pathology, Adult ; Aged ; Aged, 80 and over ; Female ; Humans ; Male ; Middle Aged ; Young Adult |
مستخلص: | We conducted a large, multicenter, retrospective survey aimed to explore the impact of tumor bone involvement in Non-Small Cell Lung Cancer.Data on clinical-pathology, skeletal outcomes and bone-directed therapies for 661 deceased patients with evidence of bone metastasis were collected and statistically analyzed. Bone metastases were evident at diagnosis in 57.5% of patients. In the remaining cases median time to bone metastases appearance was 9 months. Biphosphonates were administered in 59.6% of patients. Skeletal-related events were experienced by 57.7% of patients; the most common was the need for radiotherapy. Median time to first skeletal-related event was 6 months. Median survival after bone metastases diagnosis was 9.5 months and after the first skeletal-related event was 7 months. We created a score based on four factors used to predict the overall survival from the diagnosis of bone metastases: age >65 years, non-adenocarcinoma histology, ECOG Performance Status >2, concomitant presence of visceral metastases at the bone metastases diagnosis. The presence of more than two of these factors is associated with a worse prognosis.This study demonstrates that patients affected by Non-Small Cell Lung Cancer with bone metastases represent a heterogeneous population in terms of risk of skeletal events and survival. |
التعليقات: | Erratum in: Sci Rep. 2016;6:22205. multiple author names corrected. (PMID: 27079142) |
References: | Cancer. 2000 Mar 1;88(5):1082-90. (PMID: 10699899) Cancer Treat Rev. 2001 Jun;27(3):165-76. (PMID: 11417967) Clin Lung Cancer. 2004 Mar;5(5):267-9. (PMID: 15086964) Cancer. 2004 Jun 15;100(12):2613-21. (PMID: 15197804) Oncologist. 2004;9 Suppl 4:14-27. (PMID: 15459426) Br J Cancer. 1977 Jan;35(1):1-39. (PMID: 831755) CA Cancer J Clin. 2014 Jan-Feb;64(1):9-29. (PMID: 24399786) Cancer. 1997 Oct 15;80(8 Suppl):1588-94. (PMID: 9362426) Ann Oncol. 2005 Apr;16(4):579-84. (PMID: 15734776) N Engl J Med. 2006 Dec 14;355(24):2542-50. (PMID: 17167137) Lung Cancer. 2007 Aug;57(2):229-32. (PMID: 17451841) J Thorac Oncol. 2012 Dec;7(12):1823-9. (PMID: 23154554) J Clin Oncol. 1986 Nov;4(11):1604-14. (PMID: 3021920) |
تواريخ الأحداث: | Date Created: 20151223 Date Completed: 20161213 Latest Revision: 20220318 |
رمز التحديث: | 20221213 |
مُعرف محوري في PubMed: | PMC4687045 |
DOI: | 10.1038/srep18670 |
PMID: | 26690845 |
قاعدة البيانات: | MEDLINE |
تدمد: | 2045-2322 |
---|---|
DOI: | 10.1038/srep18670 |